Mangalam Drugs promoters declare no encumbrance in FY 2025-26

1 min read     Updated on 18 Jun 2026, 04:19 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Promoters of Mangalam Drugs and Organics declared no new encumbrances on shares in FY 2025-26, complying with SEBI regulations. The filing confirms no direct or indirect charges beyond prior disclosures.

powered bylight_fuzz_icon
43282171

*this image is generated using AI for illustrative purposes only.

Promoters of Mangalam Drugs and Organics Limited have confirmed that they did not create any encumbrance on their shares during the financial year 2025-26. This declaration, made on behalf of the promoters and members of the promoter group, ensures that no direct or indirect charges were placed on their holdings other than those already disclosed to the exchanges.

The disclosure was submitted by Shri. Govardhan M. Dhoot, a promoter of the company, to the BSE Ltd and the National Stock Exchange of India. The filing was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates such annual declarations to maintain transparency regarding shareholding patterns.

Key Details of the Filing

Aspect Details
Regulation Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Financial Year 2025-26
Declarant Shri. Govardhan M. Dhoot, Promoter
Encumbrance Status No new encumbrances created

The declaration covers the promoters, members of the promoter group, and persons acting in concert with them. By confirming the absence of new encumbrances, the company provides assurance to shareholders regarding the stability of the promoter's shareholding structure for the specified period.

Historical Stock Returns for Mangalam Drugs & Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-1.30%+0.14%+0.71%+22.96%-62.85%-79.29%

How will the absence of new encumbrances impact investor confidence in Mangalam Drugs and Organics Limited?

What are the expected capital allocation strategies of the promoters given their unencumbered shareholding status?

Could this clean shareholding structure position the company for potential mergers, acquisitions, or strategic partnerships?

Mangalam Drugs & Organics
View Company Insights
View All News
like19
dislike

Mangalam Drugs Seeks Votes for Director Re-appointment

1 min read     Updated on 20 May 2026, 04:48 AM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Mangalam Drugs & Organics Limited has initiated a postal ballot process to secure shareholder approval for the re-appointment of Shri Praveen Saxena as an Independent Director for a five-year term. The remote e-voting facility is available from May 19, 2026, to June 17, 2026, for members registered as of the May 15, 2026 cut-off date. Shri Brij Mohan Maheshwari has been appointed as the Scrutinizer to oversee the voting process.

powered bylight_fuzz_icon
40661526

*this image is generated using AI for illustrative purposes only.

Mangalam Drugs & Organics Limited has issued a notice seeking shareholder approval through a postal ballot for the re-appointment of Shri Praveen Saxena as an Independent Director. The resolution proposes a second term of five consecutive years commencing from March 21, 2026, to March 20, 2031. The notice has been dispatched pursuant to the provisions of the Companies Act, 2013, and SEBI Listing Regulations.

Postal Ballot and E-Voting Timeline

The company has established the following schedule for the remote e-voting process:

Parameter Details
Cut-Off Date Friday, May 15, 2026
Voting Opens Tuesday, May 19, 2026 (09:00 A.M.)
Voting Closes Wednesday, June 17, 2026 (05:00 P.M.)
Results Declaration On or before Friday, June 19, 2026

Shareholders whose names appear in the Register of Members or List of Beneficial Owners as on the cut-off date are entitled to cast their votes. The company has engaged National Securities Depository Limited (NSDL) to provide the remote e-voting facility.

Scrutinizer Appointment

The Board of Directors has appointed Shri Brij Mohan Maheshwari, Advocate Proprietor of M/s. B.M.M & Associates, Indore, as the Scrutinizer. He will oversee the postal ballot and e-voting process to ensure it is conducted in a fair and transparent manner. The results of the postal ballot will be submitted to the stock exchanges within 48 hours from the conclusion of the e-voting period.

Director Profile

Shri Praveen Saxena (DIN: 03199264) is an international expert with extensive experience in energy policy and renewable energy programs. He holds a Ph.D. in Physics and was conferred with the International Business Leadership Innovation Excellence Award in 2017. His first term as Independent Director expired on March 20, 2026. The Nomination and Remuneration Committee and the Board of Directors have recommended his re-appointment based on his performance and expertise.

Historical Stock Returns for Mangalam Drugs & Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-1.30%+0.14%+0.71%+22.96%-62.85%-79.29%

How might Shri Praveen Saxena's expertise in renewable energy policy influence Mangalam Drugs & Organics' strategic direction toward sustainable manufacturing practices over his second term?

What percentage of shareholder approval is typically required for independent director re-appointments in the Indian pharma sector, and how might institutional investors vote on this resolution?

Could the re-appointment of an energy policy expert as an independent director signal a potential pivot or expansion by Mangalam Drugs & Organics into green chemistry or sustainable drug manufacturing?

Mangalam Drugs & Organics
View Company Insights
View All News
like15
dislike

More News on Mangalam Drugs & Organics

1 Year Returns:-62.85%